Cyclosporine A (CsA)-induced hypertension appears to be caused in part by neurogenic vasoconstriction, but the mechanism by which CsA activates the sympathetic nervous system is unknown. In T lymphocytes, the cellular target of CsA and the macrolide immunosuppressant FK506 (as complexes with their endogenous cytoplasmic receptors, or immunophilins) is the Ca2+-calmodulin-dependent phosphatase calcineurin. The presence of calcineurin and its colocalization with immunophilin in the brain led us to hypothesize that the phosphatase also mediates CsA-induced sympathetic activation. We now report that sympathetic activity and arterial pressure in rats are increased not only by CsA but also by FK506, which is structurally unrelated to CsA but inhibits the same calcineurin-sensitive T-cell signaling pathway. In contrast, sympathetic activity and blood pressure are not increased by rapamycin, which forms an immunophilin complex that does not bind calcineurin. Furthermore, CsA-and FK506-induced sympathetic activation is attenuated for drug analogues possessing modest changes in molecular structure in a way that closely parallels the ability of each analogue to inhibit calcineurin-mediated T-cell signaling. These results implicate an important role for extralymphoid (ie, neuronal) calcineurin in mediating immunosuppressive drug toxicity. (Circulation Research 1993;73:596-602) KEY WoRDs * cyclosporine A * FKS06 * calcineurin * hypertension * sympathetic nervous system C yclosporine A (CsA) has greatly improved longterm survival after organ transplantation and the treatment of autoimmune diseases,1-6 but it also causes significant hypertension in large numbers of patients.1,7-1' Although CsA-induced hypertension seems to be caused in part by sympathetic overactivity with neurogenic vasoconstriction,12-17 the underlying mechanism by which CsA activates the sympathetic nervous system is unknown.
creasing evidence that the cellular target of both the cyclophilin-CsA and FKBP-FK506 complexes is calcineurin, a Ca 2+-calmodulin-dependent phosphatase,26,27 which is inhibited by these immunophilinligand complexes. [28] [29] [30] [31] [32] [33] The inhibition of calcineurin by immunophilin-ligand complexes appears to result in the inhibition of interleukin 2 (IL-2) gene transcription (mediated, in part, by the nuclear factor of activated T cells [NF-AT]),28-31 since the concentration of CsA, FK506, or their analogues required to inhibit 50% of NF-AT-mediated IL-2 gene transcription in human T cells is closely correlated with the inhibition of calcineurin in vitro29 and is increased significantly by either overexpression of calcineurin30 or a calcineurin catalytic subunit.3' In contrast to cyclophilin-CsA and FKBP-FK506, the FKBP-rapamycin complex does not interact with calcineurin and does not inhibit IL-2 gene transcription. Rather, this complex appears to interrupt a different T-cell signaling pathway. 24 Calcineurin, which was first discovered in neural rather than lymphoid tissue,2627 is colocalized with immunophilins in specific brain regions that are involved in the sympathetic control of blood pressure.34,35 Therefore, we asked whether inhibition of neuronal calcineurin might play an important physiological role in mediating CsA-induced sympathetic activation and hypertension. We now report that sympathetic activity and arterial pressure in rats are increased not only by CsA but also by FK506, which is structurally unrelated to CsA but inhibits the same calcineurin-sensitive T-cell signaling pathway. 28 
In Vitro Studies
The phosphatase activity of bovine brain calcineurin was assayed by incubating calcineurin with calmodulin, immunophilin ligands, and immunophiin with a 32P-labeled phosphopeptide substrate as previously described. 28 The rotamase (cis-trans peptidyl prolyl isomerase) activity of the immunophilins was assayed by incubating immunophilin ligands with immunophilin and a test peptide (succinyl-Ala-Leu-Pro-Phe-p-nitroanilide) as previously described.24
The inhibition constants, Ki (nanomolar) for the phosphatase activity of calcineurin and Ki for the rotamase activity of immunophilins, were calculated by kinetic analyses as previously described. 24 Results Sympathetic activity and blood pressure increased markedly with both CsA and FK506 but did not increase and even decreased with rapamycin (Table and Fig 1) . Intravenous infusion of vehicle had no effect on either sympathetic nerve activity or blood pressure (Table) .
An initial dose of either CsA or FK506 greatly attenuated the increases in sympathetic activity and arterial pressure evoked by a subsequent dose of the same or other drug (Fig 2) . An initial dose of either CsA or FK506, however, did not attenuate the increases in sympathetic activity (and arterial pressure) evoked by the stimulation of somatic afferents, a nonspecific test of sympathetic reactivity. Before any drugs were infused, this test caused sympathetic activity to increase from 19+4 to 78±9 Hz (A59+5 Hz); after the second drug infusion, it increased sympathetic activity from an already elevated value of 49±10 to 118±13 Hz (A69±+10 Hz). For analogues of both CsA and FK506, sympathetic activity was strongly associated with inhibition of calcineurin-mediated NF-AT activity, which regulates IL-2 gene transcription (Table and Fig 4) . Sympathetic activity and blood pressure increased only with those immunophilin ligands whose immunophilin complexes inhibit the phosphatase activity of calcineurin and calcineurinmediated inhibition of NF-AT activity. MeBm2t'-CsA, whose immunophilin complex is a slightly less potent inhibitor of NF-AT activity than is that of CsA, caused a significant increase in sympathetic activity, which tended to be slightly less than that caused by CsA. FK523, whose immunophilin complex causes 60% less inhibition of NF-AT-mediated transcriptional activation than does that of FK506, caused an increase in sympathetic activity that was 60% smaller (P<.05) than that produced by the same dose of FK506.
In contrast, sympathetic activity was not increased but rather decreased (P<.05) by MeAla6-CsA, 15-0-demethyl-FK520, and rapamycin, three compounds that potently inhibit the rotamase activity of immunophilins but have no effect on either the phosphatase activity of calcineurin or NF-AT-mediated transcriptional activation (Table) ally related to FK506 but does not bind calcineurin, strongly suggests that sympathetic activation is a specific property of only those immunosuppressive drugs whose immunophilin complexes inhibit calcineurin.
Cyclophilin-CsA and FKBP-FK506 complexes have been shown to bind competitively to calcineurin, indicating that their binding sites are similar or overlapping.28 Thus, our demonstration of tachyphylaxis and mutual inhibition in the sympathetic nerve and blood pressure responses to CsA and FK506 strongly suggests that increases in sympathetic activity produced by both drugs are caused by a similar action of these two different immunophilin complexes on a common saturable neuronal target such as calcineurin.
The strongest evidence in support of this hypothesis is that the CsA-and FK506-induced sympathetic activation is attenuated by the same specific structural alterations in these molecules that attenuate their ability to inhibit the phosphatase activity of brain calcineurin and calcineurin-mediated T-cell signaling. Although these data do not prove a causal role for calcineurin in mediating sympathetic overactivity, the strength of the observed correlations is remarkable, since sympathetic activity was measured in intact rats, whereas calcineurin activity was assayed either in vitro or as a function of NF-AT inhibition in T cells. The parallelism between the effects of immunophilin ligands on the immune and sympathetic systems is further suggested by the additional finding that sympathetic activation, like immune suppression, is readily dissociated from the immunophilin-ligand inhibition of rotamase.
An unexpected finding was that sympathetic activity decreased with MeAlaW-CsA, 15 -O-demethyl-FK520, and rapamycin, three immunophilin ligands that have no effect on calcineurin. Although the underlying mechanism is unknown, a possible explanation might be the presence of endogenous immunophilin ligands that, when complexed with immunophilins, inhibit calcineurin activity and thereby tonically stimulate sympathetic activity. Although these three exogenous ligands do not affect calcineurin directly, they could compete with hypothetical endogenous ligands for immunophilins and thereby reduce the tonic inhibition of calcineurin and the tonic stimulation of sympathetic activity. 
